

1. [NPPA asks drug makers to furnish prices of 56 formulations](#) - PTI flash

In an effort to fix the ceiling prices of 56 drug formulations, including those for epilepsy, diabetes and heart diseases, the government has given drug makers and marketing firms a week to furnish their prices-to-retailer and MAT for August 2015.

The formulations also includes those targeting bipolar disorder, dietary supplements, anticoagulants, HIV/AIDS, drug price regulator National Pharmaceutical Pricing Authority (NPPA) said in a statement.

Also appeared in [Moneycontrol.com](#)

1. [NPPA asks drug makers to furnish prices of 56 formulations](#)- PTI flash
2. [India sacks some foreign-funded consultants; health programmes may suffer](#) – Reuters
3. [DPCO dose too strong, hits medicine access: IIM study](#) – Financial Express
4. [Subir Roy: The shameful state of MCI](#) – Business Standard
5. [New U.S. inversion rules threaten Pfizer-Allergan deal](#) – Reuters
6. [Cipla bets on speciality drugs in US; aims for commercial launch by 2020](#) – Economic Times
7. [India should join TPP to maintain trade advantages in generics: Patent experts](#) – Pharmabiz
8. [Pharmaceutical zones to curb drug imports from China: Govt](#) – Hindustan Times
9. [Govt taking calibrated approach in opening up sectors for FDI: Nirmala Sitharaman](#) – Financial Express

2. [India sacks some foreign-funded consultants; health programmes may suffer](#) – Reuters

India is dismissing dozens of foreign-funded health experts working inside the government, a move seen as part of a broader clampdown on the influence of non-government organisations (NGOs) on public policy.

The loss of these professionals, most of whom are Indian nationals, has raised concern that signature programmes to combat HIV/AIDS and tuberculosis may suffer just as they face funding shortages due to slow bureaucracy.

3. [DPCO dose too strong, hits medicine access: IIM study](#) – Financial Express

The Drug Price Control Order (DPCO) 2013 that expanded the span of regulation to 60% of the \$22-billion Indian pharmaceutical market appears to have come a cropper. A recent study confirmed what many analysts feared: That regulation of the kind prevalent now could dent access to medicines, an outcome opposite to what the government wants.

4. [Subir Roy: The shameful state of MCI](#) – Business Standard

The parliamentary standing committee for the Union Ministry of Health and Family Welfare has produced a report on the Medical Council of India (MCI), which would shame all those at the helm if they were capable of such feeling. The transgressions of the regulatory body under the ministry, charged with overseeing medical education and doctors' right to practice and ethical conduct, are well known. The report has validated a lot of the relevant media coverage and, through the committee's own investigations, laid down solid fundamentals for bringing about systemic change.

5. [New U.S. inversion rules threaten Pfizer-Allergan deal](#) – Reuters

The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate "inversions," with the pending \$160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.

The changes, less than a year before President Barack Obama ends his term, follow sharp political criticism of Pfizer's and Allergan's merger, which would be the largest inversion deal ever. While the rules did not single out this deal, one of the provisions takes aim directly at it.

Appeared in [DNA](#)

6. [Cipla bets on speciality drugs in US; aims for commercial launch by 2020](#) – Economic Times

Cipla has set its sights on building a pipeline of speciality drugs in the United States. The company, India's third-largest drugmaker, plans to deploy more funds for research and development in respiratory, dermatology, neurology and oncology segments and hopes for the first commercial launch in the US around 2020.

7. [India should join TPP to maintain trade advantages in generics: Patent experts](#) – Pharmabiz

India which has stronghold in manufacture and export of generic drugs globally could lose its trade advantages in generics if it does not join US-led trade pact Trans Pacific Partnership Agreement (TTP), involving twelve Pacific Rim countries and concerning duty free trade, reduced tariffs and mutual regulatory recognition to members, according to patent experts.

8. [Pharmaceutical zones to curb drug imports from China: Govt](#) – Hindustan Times

In a two-pronged strategy to promote the Make in India initiative and curb dependence of the pharmaceutical industry on Chinese imports, commerce and industry minister Nirmala Sitharaman on Tuesday said the government is considering setting up of specified pharmaceutical zones.

The zones, aimed at easing manufacturing, and research and development of active pharmaceutical ingredients (API), will also help boost exports. They will have an additional advantage of reducing India's trade deficit with China.

9. [Govt taking calibrated approach in opening up sectors for FDI: Nirmala Sitharaman](#) – Financial Express

The government is taking a calibrated approach in opening up sectors like retail for foreign direct investments, as it's careful in not putting at stake self-created jobs of a large number of people, commerce and industry minister Nirmala Sitharaman said on Tuesday.